Be a Smart Investor
Monday, February 27, 2017
Biotech Stocks Facing FDA Decision In March
The month of February saw the FDA approve the second drug for Duchenne muscular dystrophy namely Emflaza.
from RTT - Biotech http://ift.tt/2mBQJxW
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment